[go: up one dir, main page]

DK3233843T3 - Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere - Google Patents

Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere Download PDF

Info

Publication number
DK3233843T3
DK3233843T3 DK15816893T DK15816893T DK3233843T3 DK 3233843 T3 DK3233843 T3 DK 3233843T3 DK 15816893 T DK15816893 T DK 15816893T DK 15816893 T DK15816893 T DK 15816893T DK 3233843 T3 DK3233843 T3 DK 3233843T3
Authority
DK
Denmark
Prior art keywords
hydraxamic
isoxazole
acid compounds
lpxc inhibitors
lpxc
Prior art date
Application number
DK15816893T
Other languages
English (en)
Inventor
Jiping Fu
Xianming Jin
Subramanian Karur
Guillaume Lapointe
Ann Marie Madera
Zachary Kevin Sweeney
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3233843T3 publication Critical patent/DK3233843T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15816893T 2014-12-16 2015-12-15 Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere DK3233843T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462092402P 2014-12-16 2014-12-16
PCT/IB2015/059631 WO2016097995A1 (en) 2014-12-16 2015-12-15 Isoxazole hydroxamic acid compounds as lpxc inhibitors

Publications (1)

Publication Number Publication Date
DK3233843T3 true DK3233843T3 (da) 2019-11-18

Family

ID=55025302

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15816893T DK3233843T3 (da) 2014-12-16 2015-12-15 Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere

Country Status (42)

Country Link
US (3) US9549916B2 (da)
EP (1) EP3233843B1 (da)
JP (1) JP6697466B2 (da)
KR (1) KR20170094214A (da)
CN (1) CN107001295B (da)
AR (1) AR107428A1 (da)
AU (1) AU2015365455B2 (da)
BR (1) BR112017011422A2 (da)
CA (1) CA2969803A1 (da)
CL (1) CL2017001460A1 (da)
CO (1) CO2017005870A2 (da)
CR (1) CR20170260A (da)
CU (1) CU24443B1 (da)
CY (1) CY1122305T1 (da)
DK (1) DK3233843T3 (da)
EA (1) EA032138B1 (da)
EC (1) ECSP17045737A (da)
ES (1) ES2756300T3 (da)
GT (1) GT201700132A (da)
HR (1) HRP20192009T1 (da)
HU (1) HUE047225T2 (da)
IL (1) IL252373B (da)
JO (1) JO3818B1 (da)
LT (1) LT3233843T (da)
MA (1) MA41185B1 (da)
ME (1) ME03546B (da)
MX (1) MX2017007980A (da)
MY (1) MY195743A (da)
PE (1) PE20171044A1 (da)
PH (1) PH12017501019B1 (da)
PL (1) PL3233843T3 (da)
PT (1) PT3233843T (da)
RS (1) RS59507B1 (da)
SG (1) SG11201704053WA (da)
SI (1) SI3233843T1 (da)
SM (1) SMT201900631T1 (da)
SV (1) SV2017005462A (da)
TN (1) TN2017000207A1 (da)
TW (1) TWI693215B (da)
UA (1) UA121225C2 (da)
UY (1) UY36448A (da)
WO (1) WO2016097995A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107698569B (zh) 2013-05-17 2020-11-27 因赛特公司 作为jak抑制剂的联吡唑衍生物
HRP20201524T1 (hr) 2016-06-14 2021-03-05 Novartis Ag Kristalni oblik (r)-4-(5-(ciklopropiletinil) izoksazol-3 -il)-n-hidroksi-2-metil-2-(metilsufonil) butanamid kao antibakterijsko sredstvo
CN107434766A (zh) * 2017-08-09 2017-12-05 凯莱英医药集团（天津）股份有限公司 烷烃羟胺类化合物的合成装置及连续合成方法
KR20240157777A (ko) 2018-02-16 2024-11-01 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
JP7495395B2 (ja) 2018-09-20 2024-06-04 ブラックスミス メディシンズ，インク． 抗菌性化合物
KR20210093884A (ko) * 2018-11-21 2021-07-28 다이쇼 세이야꾸 가부시끼가이샤 신규 이미다졸 유도체
BR112022024632A2 (pt) 2020-06-02 2023-02-28 Incyte Corp Processos para preparar um inibidor de jak1
MX2023006542A (es) 2020-12-08 2023-08-25 Incyte Corp Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.
CN112603936B (zh) * 2020-12-28 2022-08-02 仲恺农业工程学院 一种抑制气单胞菌属的组合物及其制备方法与应用
JP2024507140A (ja) * 2021-02-11 2024-02-16 ブラックスミス メディシンズ，インク． 抗菌性化合物
AR124841A1 (es) * 2021-02-11 2023-05-10 Forge Therapeutics Inc Compuestos antibacterianos
DK4333840T3 (da) 2021-05-03 2025-11-24 Incyte Corp Jak1-vejinhibitorer til behandling af prurigo nodularis
AU2022357226A1 (en) * 2021-09-28 2024-05-02 Blacksmith Medicines, Inc. Lpxc inhibitors and uses thereof
CN119923396A (zh) * 2022-09-28 2025-05-02 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和其医药上的用途
WO2024067812A1 (zh) * 2022-09-28 2024-04-04 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
DE59009528D1 (de) 1989-09-22 1995-09-21 Basf Ag Carbonsäureamide.
AU4055697A (en) 1996-08-16 1998-03-06 Schering Corporation Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
EP1025228A4 (en) 1997-10-21 2002-09-18 Human Genome Sciences Inc HUMAN PROTEIN TR11, TR11SV1 AND TR11SV2 SIMILAR TO THE TUMOR NECROSIS FACTOR RECEPTOR
WO1999040196A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
DE60036945T2 (de) 1999-07-12 2008-08-21 Genentech, Inc., South San Francisco Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
KR101076018B1 (ko) 2003-01-08 2011-10-21 유니버시티 오브 워싱톤 항균제
KR20060052681A (ko) 2003-05-23 2006-05-19 와이어쓰 Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도
WO2005007190A1 (en) 2003-07-11 2005-01-27 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
EP1692318A4 (en) 2003-12-02 2008-04-02 Genzyme Corp COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
US7812135B2 (en) 2005-03-25 2010-10-12 Tolerrx, Inc. GITR-binding antibodies
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
MX2010008786A (es) 2008-02-11 2010-12-01 Curetech Ltd Anticuerpos monoclonales para tratamiento de tumores.
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
AU2009266873A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc TGF-beta antagonist multi-target binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
EP2324055A2 (en) 2008-08-25 2011-05-25 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
WO2010030002A1 (ja) 2008-09-12 2010-03-18 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
US8722686B2 (en) * 2008-09-19 2014-05-13 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
SMT202400136T1 (it) 2008-12-09 2024-05-14 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP3023438B1 (en) 2009-09-03 2020-03-11 Merck Sharp & Dohme Corp. Anti-gitr antibodies
JP5671545B2 (ja) * 2009-10-13 2015-02-18 ファイザー・インク 抗菌薬として有用なｃ結合ヒドロキサム酸誘導体
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011073845A1 (en) * 2009-12-16 2011-06-23 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
RS55229B1 (sr) 2009-12-29 2017-02-28 Emergent Product Dev Seattle Heterodimerni vezujući proteini i njihove upotrebe
US8877754B2 (en) 2010-09-06 2014-11-04 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
JP2014501716A (ja) 2010-11-10 2014-01-23 アカオジェン インコーポレイテッド ヒドロキサム酸誘導体および細菌感染の処置におけるその使用
ES2626457T3 (es) 2011-03-07 2017-07-25 Pfizer Inc. Derivados de fluoro-piridinona útiles como agentes antibacterianos
US8809333B2 (en) * 2011-04-08 2014-08-19 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
CN103717582B (zh) * 2011-04-08 2015-09-30 辉瑞大药厂 用作抗菌剂的异*唑衍生物
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
SMT202000561T1 (it) 2011-11-28 2021-01-05 Merck Patent Gmbh Anticorpi anti-pd-l1 e usi relativi
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections

Also Published As

Publication number Publication date
SV2017005462A (es) 2018-04-04
HUE047225T2 (hu) 2020-04-28
IL252373A0 (en) 2017-07-31
CR20170260A (es) 2017-08-21
IL252373B (en) 2019-11-28
WO2016097995A1 (en) 2016-06-23
JP6697466B2 (ja) 2020-05-20
CL2017001460A1 (es) 2017-12-22
PL3233843T3 (pl) 2020-04-30
MX2017007980A (es) 2017-09-29
US20160166548A1 (en) 2016-06-16
EP3233843B1 (en) 2019-10-16
CO2017005870A2 (es) 2017-10-20
ECSP17045737A (es) 2019-02-28
PE20171044A1 (es) 2017-07-19
AU2015365455B2 (en) 2019-01-17
CU20170084A7 (es) 2017-11-07
UY36448A (es) 2016-07-29
MY195743A (en) 2023-02-08
CU24443B1 (es) 2019-10-04
EA032138B1 (ru) 2019-04-30
US20170088525A1 (en) 2017-03-30
EP3233843A1 (en) 2017-10-25
PH12017501019B1 (en) 2020-06-05
EA201791353A1 (ru) 2017-10-31
CY1122305T1 (el) 2021-01-27
AU2015365455A1 (en) 2017-06-08
US10029994B2 (en) 2018-07-24
MA41185B1 (fr) 2019-12-31
GT201700132A (es) 2019-10-10
TWI693215B (zh) 2020-05-11
AR107428A1 (es) 2018-05-02
PH12017501019A1 (en) 2017-12-04
RS59507B1 (sr) 2019-12-31
SMT201900631T1 (it) 2020-01-14
TW201629024A (zh) 2016-08-16
HRP20192009T1 (hr) 2020-02-07
JO3818B1 (ar) 2021-01-31
CN107001295A (zh) 2017-08-01
SI3233843T1 (sl) 2019-12-31
BR112017011422A2 (pt) 2018-04-03
LT3233843T (lt) 2019-12-10
US20180030004A1 (en) 2018-02-01
TN2017000207A1 (en) 2018-10-19
ME03546B (me) 2020-07-20
US9549916B2 (en) 2017-01-24
KR20170094214A (ko) 2017-08-17
CA2969803A1 (en) 2016-06-23
UA121225C2 (uk) 2020-04-27
PT3233843T (pt) 2019-11-26
JP2018500333A (ja) 2018-01-11
US9815804B2 (en) 2017-11-14
SG11201704053WA (en) 2017-06-29
ES2756300T3 (es) 2020-04-27
CN107001295B (zh) 2021-02-02

Similar Documents

Publication Publication Date Title
DK3233843T3 (da) Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
IL250923A0 (en) Novel compounds as rearranged during transfection (ret) inhibitors
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3377488T3 (da) Heterocykliske forbindelser som immunomodulatorer
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3105226T3 (da) Cyclopropylaminer som lsd1-inhibitorer
LT3436461T (lt) Pirolotriazino junginiai kaip tam inhibitoriai
DK3190113T3 (da) Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist
DK3357919T3 (da) Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser
LT3137169T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
HUE042409T2 (hu) Eljárás diaril-tiohidantoin vegyület elõállítására
LT3160956T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
HUE058852T2 (hu) Lizinspecifikus demetiláz-1 inhibitorai
DK3294713T3 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
PT3116498T (pt) Formulação para análogos anticolinérgicos suaves
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
DK3256462T3 (da) Substituerede 2-thioimidazolyl-carboxamider som skadedyrsbekæmpelsesmiddel
DK3544981T3 (da) Benzodiazoliumforbindelser som enac-inhibitorer
DK3717488T3 (da) Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
DK3202766T3 (da) Isoxazolderivat som muteret isocitratdehydrogenase 1-inhibitor
HUE042349T2 (hu) Eljárás diariltiohidantoin vegyület elõállítására
DK3137658T3 (da) Anvendelse af kendte forbindelser som d-aminosyreoxidase-inhibitorer